Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children

Coagulation and fibrinolytic factors in the blood were measured during heparinurokinase (UK)-pulse combined therapy in order to investigate the background for the availability of the therapy. Five patients with nephritis resistant to conventional treatment were treated with this combined therapy (he...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nihon Jinzo Gakkai shi 1993/10/25, Vol.35(10), pp.1155-1161
Hauptverfasser: KOITABASHI, YASUSHI, IKOMA, MASAAKI, SHIBAWAKA, TSUGUO, YAMAGUCHI, YOSHIYA, MIO, HITOSHI, DOI, KEIJI, MEGURO, TAKASHI, YAMADA, KANEO
Format: Artikel
Sprache:jpn
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1161
container_issue 10
container_start_page 1155
container_title Nihon Jinzo Gakkai shi
container_volume 35
creator KOITABASHI, YASUSHI
IKOMA, MASAAKI
SHIBAWAKA, TSUGUO
YAMAGUCHI, YOSHIYA
MIO, HITOSHI
DOI, KEIJI
MEGURO, TAKASHI
YAMADA, KANEO
description Coagulation and fibrinolytic factors in the blood were measured during heparinurokinase (UK)-pulse combined therapy in order to investigate the background for the availability of the therapy. Five patients with nephritis resistant to conventional treatment were treated with this combined therapy (heparin:350-450 U/kg day, continuously i.v.during the therapy;UK:5000 IU/kg/2hrs, i.v., two times a day, for 3 days=l Kur; methyl-prednisolone 20mg/kg/2hrs, d.i.v., for 3 days=l Kur; 3 Kurs of UK and 3 Kurs of pulse were alternately administered).1) Blood levels of α2-plasmin inhibitor (α2PT) antigen were decreased and those of α2-plasmin inhibitor· plasmin complex (α2-PI. PmC) were elevated during 3 Kurs of UK administration.Accordingly, activation of the fibrinolytic system was confirmed during the combined therapy, suggesting that both α2-PI and α2-PI·PmC were relevant in monitoring the fibrinolytic state in blood.2) Both tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAT-1) levels were sustained continuosly in the elevated levels in the blood during both UK administration and pulse therapy. This movement of t-PA and PAI-1 was independent of that of the other fibrinolytic factors, such as α2-PI, α2-PI·PmC and plasminogen.3) Inflammatory reactants such as fibrinogen, α2-PI, α2macroglobulin and α1-antitrypsin decreased more significantly during this heparinurokinase-pulse combined therapy than during our previous combined therapy consisting of only heparin and urokinase. Therefore, we conclude that the anti-inflammatory effect was reinforced by adding the pulse therapy and that the combined therapy had some effect on the release of t-PA from vascular endotherial cells
doi_str_mv 10.14842/jpnjnephrol1959.35.1155
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76146670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76146670</sourcerecordid><originalsourceid>FETCH-LOGICAL-j249t-7cc607c9a0492588beda49907d2bd81e16049ffed0d00563016fdf35fbb278023</originalsourceid><addsrcrecordid>eNpdkc1u3CAUhVHVKh1N8wiVWHXnKRhj42U16p8UtZtkbfFzGTPF4AKONC_U5yxpRll0c-9F59MBzkUIU3Kgnejaj-c1nAOsc4qejnw8MH6glPNXaEeF6BoytOI12hEmeNPW8hbd5uwUoWIgjA_dDboZOOGs4zv05zjLcIKMo8U6ytPmZXExYBkMtk4lF6K_FKexlbrEVDmVIT2CwWar4gnPsMo6NFuKv1yQGZp18xmq2aJcqFyZIcn1gm1M-N-jXXEZJ8guFxkKLrGy4RHC073S45JAlqUesQtYz86bBOEdemNltb299j16-PL5_vitufv59fvx011zbruxNIPWPRn0KEk3tlwIBUZ240gG0yojKNC-CtaCIYYQ3jNCe2ss41apdhCkZXv04dl3TfH3BrlMi8savJcB4panoadd39cY9-j9FdzUAmZak1tkukzXYKv-41k_11-e4EWXqYbpYfpvhRPjEyXX-rTLF1DPMk0Q2F8vfqCV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76146670</pqid></control><display><type>article</type><title>Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children</title><source>J-STAGE Free</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>KOITABASHI, YASUSHI ; IKOMA, MASAAKI ; SHIBAWAKA, TSUGUO ; YAMAGUCHI, YOSHIYA ; MIO, HITOSHI ; DOI, KEIJI ; MEGURO, TAKASHI ; YAMADA, KANEO</creator><creatorcontrib>KOITABASHI, YASUSHI ; IKOMA, MASAAKI ; SHIBAWAKA, TSUGUO ; YAMAGUCHI, YOSHIYA ; MIO, HITOSHI ; DOI, KEIJI ; MEGURO, TAKASHI ; YAMADA, KANEO</creatorcontrib><description>Coagulation and fibrinolytic factors in the blood were measured during heparinurokinase (UK)-pulse combined therapy in order to investigate the background for the availability of the therapy. Five patients with nephritis resistant to conventional treatment were treated with this combined therapy (heparin:350-450 U/kg day, continuously i.v.during the therapy;UK:5000 IU/kg/2hrs, i.v., two times a day, for 3 days=l Kur; methyl-prednisolone 20mg/kg/2hrs, d.i.v., for 3 days=l Kur; 3 Kurs of UK and 3 Kurs of pulse were alternately administered).1) Blood levels of α2-plasmin inhibitor (α2PT) antigen were decreased and those of α2-plasmin inhibitor· plasmin complex (α2-PI. PmC) were elevated during 3 Kurs of UK administration.Accordingly, activation of the fibrinolytic system was confirmed during the combined therapy, suggesting that both α2-PI and α2-PI·PmC were relevant in monitoring the fibrinolytic state in blood.2) Both tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAT-1) levels were sustained continuosly in the elevated levels in the blood during both UK administration and pulse therapy. This movement of t-PA and PAI-1 was independent of that of the other fibrinolytic factors, such as α2-PI, α2-PI·PmC and plasminogen.3) Inflammatory reactants such as fibrinogen, α2-PI, α2macroglobulin and α1-antitrypsin decreased more significantly during this heparinurokinase-pulse combined therapy than during our previous combined therapy consisting of only heparin and urokinase. Therefore, we conclude that the anti-inflammatory effect was reinforced by adding the pulse therapy and that the combined therapy had some effect on the release of t-PA from vascular endotherial cells</description><identifier>ISSN: 0385-2385</identifier><identifier>EISSN: 1884-0728</identifier><identifier>DOI: 10.14842/jpnjnephrol1959.35.1155</identifier><identifier>PMID: 7505345</identifier><language>jpn</language><publisher>Japan: Japanese Society of Nephrology</publisher><subject>Adolescent ; alpha-2-Antiplasmin - metabolism ; Antifibrinolytic Agents ; Blood Coagulation Factors - metabolism ; Child ; Child, Preschool ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Fibrinolysin - metabolism ; Fibrinolysis ; Heparin - administration &amp; dosage ; heparin-urokinase-pulse combined therapy, α2-plasmin inhibitor · plasmin complex (α2-PI · PmC), tissue-plasminogen activator (t-PA), coagulation factors, fibrinolytic factors ; Humans ; Male ; Nephritis - blood ; Nephritis - drug therapy ; Tissue Plasminogen Activator - metabolism ; Urokinase-Type Plasminogen Activator - administration &amp; dosage</subject><ispartof>The Japanese Journal of Nephrology, 1993/10/25, Vol.35(10), pp.1155-1161</ispartof><rights>Japanese Society of Nephrology</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1884,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7505345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOITABASHI, YASUSHI</creatorcontrib><creatorcontrib>IKOMA, MASAAKI</creatorcontrib><creatorcontrib>SHIBAWAKA, TSUGUO</creatorcontrib><creatorcontrib>YAMAGUCHI, YOSHIYA</creatorcontrib><creatorcontrib>MIO, HITOSHI</creatorcontrib><creatorcontrib>DOI, KEIJI</creatorcontrib><creatorcontrib>MEGURO, TAKASHI</creatorcontrib><creatorcontrib>YAMADA, KANEO</creatorcontrib><title>Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children</title><title>Nihon Jinzo Gakkai shi</title><addtitle>Jpn J Nephrol</addtitle><description>Coagulation and fibrinolytic factors in the blood were measured during heparinurokinase (UK)-pulse combined therapy in order to investigate the background for the availability of the therapy. Five patients with nephritis resistant to conventional treatment were treated with this combined therapy (heparin:350-450 U/kg day, continuously i.v.during the therapy;UK:5000 IU/kg/2hrs, i.v., two times a day, for 3 days=l Kur; methyl-prednisolone 20mg/kg/2hrs, d.i.v., for 3 days=l Kur; 3 Kurs of UK and 3 Kurs of pulse were alternately administered).1) Blood levels of α2-plasmin inhibitor (α2PT) antigen were decreased and those of α2-plasmin inhibitor· plasmin complex (α2-PI. PmC) were elevated during 3 Kurs of UK administration.Accordingly, activation of the fibrinolytic system was confirmed during the combined therapy, suggesting that both α2-PI and α2-PI·PmC were relevant in monitoring the fibrinolytic state in blood.2) Both tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAT-1) levels were sustained continuosly in the elevated levels in the blood during both UK administration and pulse therapy. This movement of t-PA and PAI-1 was independent of that of the other fibrinolytic factors, such as α2-PI, α2-PI·PmC and plasminogen.3) Inflammatory reactants such as fibrinogen, α2-PI, α2macroglobulin and α1-antitrypsin decreased more significantly during this heparinurokinase-pulse combined therapy than during our previous combined therapy consisting of only heparin and urokinase. Therefore, we conclude that the anti-inflammatory effect was reinforced by adding the pulse therapy and that the combined therapy had some effect on the release of t-PA from vascular endotherial cells</description><subject>Adolescent</subject><subject>alpha-2-Antiplasmin - metabolism</subject><subject>Antifibrinolytic Agents</subject><subject>Blood Coagulation Factors - metabolism</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Drug Administration Schedule</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fibrinolysin - metabolism</subject><subject>Fibrinolysis</subject><subject>Heparin - administration &amp; dosage</subject><subject>heparin-urokinase-pulse combined therapy, α2-plasmin inhibitor · plasmin complex (α2-PI · PmC), tissue-plasminogen activator (t-PA), coagulation factors, fibrinolytic factors</subject><subject>Humans</subject><subject>Male</subject><subject>Nephritis - blood</subject><subject>Nephritis - drug therapy</subject><subject>Tissue Plasminogen Activator - metabolism</subject><subject>Urokinase-Type Plasminogen Activator - administration &amp; dosage</subject><issn>0385-2385</issn><issn>1884-0728</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkc1u3CAUhVHVKh1N8wiVWHXnKRhj42U16p8UtZtkbfFzGTPF4AKONC_U5yxpRll0c-9F59MBzkUIU3Kgnejaj-c1nAOsc4qejnw8MH6glPNXaEeF6BoytOI12hEmeNPW8hbd5uwUoWIgjA_dDboZOOGs4zv05zjLcIKMo8U6ytPmZXExYBkMtk4lF6K_FKexlbrEVDmVIT2CwWar4gnPsMo6NFuKv1yQGZp18xmq2aJcqFyZIcn1gm1M-N-jXXEZJ8guFxkKLrGy4RHC073S45JAlqUesQtYz86bBOEdemNltb299j16-PL5_vitufv59fvx011zbruxNIPWPRn0KEk3tlwIBUZ240gG0yojKNC-CtaCIYYQ3jNCe2ss41apdhCkZXv04dl3TfH3BrlMi8savJcB4panoadd39cY9-j9FdzUAmZak1tkukzXYKv-41k_11-e4EWXqYbpYfpvhRPjEyXX-rTLF1DPMk0Q2F8vfqCV</recordid><startdate>199310</startdate><enddate>199310</enddate><creator>KOITABASHI, YASUSHI</creator><creator>IKOMA, MASAAKI</creator><creator>SHIBAWAKA, TSUGUO</creator><creator>YAMAGUCHI, YOSHIYA</creator><creator>MIO, HITOSHI</creator><creator>DOI, KEIJI</creator><creator>MEGURO, TAKASHI</creator><creator>YAMADA, KANEO</creator><general>Japanese Society of Nephrology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>199310</creationdate><title>Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children</title><author>KOITABASHI, YASUSHI ; IKOMA, MASAAKI ; SHIBAWAKA, TSUGUO ; YAMAGUCHI, YOSHIYA ; MIO, HITOSHI ; DOI, KEIJI ; MEGURO, TAKASHI ; YAMADA, KANEO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-j249t-7cc607c9a0492588beda49907d2bd81e16049ffed0d00563016fdf35fbb278023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>jpn</language><creationdate>1993</creationdate><topic>Adolescent</topic><topic>alpha-2-Antiplasmin - metabolism</topic><topic>Antifibrinolytic Agents</topic><topic>Blood Coagulation Factors - metabolism</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Drug Administration Schedule</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fibrinolysin - metabolism</topic><topic>Fibrinolysis</topic><topic>Heparin - administration &amp; dosage</topic><topic>heparin-urokinase-pulse combined therapy, α2-plasmin inhibitor · plasmin complex (α2-PI · PmC), tissue-plasminogen activator (t-PA), coagulation factors, fibrinolytic factors</topic><topic>Humans</topic><topic>Male</topic><topic>Nephritis - blood</topic><topic>Nephritis - drug therapy</topic><topic>Tissue Plasminogen Activator - metabolism</topic><topic>Urokinase-Type Plasminogen Activator - administration &amp; dosage</topic><toplevel>online_resources</toplevel><creatorcontrib>KOITABASHI, YASUSHI</creatorcontrib><creatorcontrib>IKOMA, MASAAKI</creatorcontrib><creatorcontrib>SHIBAWAKA, TSUGUO</creatorcontrib><creatorcontrib>YAMAGUCHI, YOSHIYA</creatorcontrib><creatorcontrib>MIO, HITOSHI</creatorcontrib><creatorcontrib>DOI, KEIJI</creatorcontrib><creatorcontrib>MEGURO, TAKASHI</creatorcontrib><creatorcontrib>YAMADA, KANEO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Nihon Jinzo Gakkai shi</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOITABASHI, YASUSHI</au><au>IKOMA, MASAAKI</au><au>SHIBAWAKA, TSUGUO</au><au>YAMAGUCHI, YOSHIYA</au><au>MIO, HITOSHI</au><au>DOI, KEIJI</au><au>MEGURO, TAKASHI</au><au>YAMADA, KANEO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children</atitle><jtitle>Nihon Jinzo Gakkai shi</jtitle><addtitle>Jpn J Nephrol</addtitle><date>1993-10</date><risdate>1993</risdate><volume>35</volume><issue>10</issue><spage>1155</spage><epage>1161</epage><pages>1155-1161</pages><issn>0385-2385</issn><eissn>1884-0728</eissn><abstract>Coagulation and fibrinolytic factors in the blood were measured during heparinurokinase (UK)-pulse combined therapy in order to investigate the background for the availability of the therapy. Five patients with nephritis resistant to conventional treatment were treated with this combined therapy (heparin:350-450 U/kg day, continuously i.v.during the therapy;UK:5000 IU/kg/2hrs, i.v., two times a day, for 3 days=l Kur; methyl-prednisolone 20mg/kg/2hrs, d.i.v., for 3 days=l Kur; 3 Kurs of UK and 3 Kurs of pulse were alternately administered).1) Blood levels of α2-plasmin inhibitor (α2PT) antigen were decreased and those of α2-plasmin inhibitor· plasmin complex (α2-PI. PmC) were elevated during 3 Kurs of UK administration.Accordingly, activation of the fibrinolytic system was confirmed during the combined therapy, suggesting that both α2-PI and α2-PI·PmC were relevant in monitoring the fibrinolytic state in blood.2) Both tissue-plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAT-1) levels were sustained continuosly in the elevated levels in the blood during both UK administration and pulse therapy. This movement of t-PA and PAI-1 was independent of that of the other fibrinolytic factors, such as α2-PI, α2-PI·PmC and plasminogen.3) Inflammatory reactants such as fibrinogen, α2-PI, α2macroglobulin and α1-antitrypsin decreased more significantly during this heparinurokinase-pulse combined therapy than during our previous combined therapy consisting of only heparin and urokinase. Therefore, we conclude that the anti-inflammatory effect was reinforced by adding the pulse therapy and that the combined therapy had some effect on the release of t-PA from vascular endotherial cells</abstract><cop>Japan</cop><pub>Japanese Society of Nephrology</pub><pmid>7505345</pmid><doi>10.14842/jpnjnephrol1959.35.1155</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0385-2385
ispartof The Japanese Journal of Nephrology, 1993/10/25, Vol.35(10), pp.1155-1161
issn 0385-2385
1884-0728
language jpn
recordid cdi_proquest_miscellaneous_76146670
source J-STAGE Free; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adolescent
alpha-2-Antiplasmin - metabolism
Antifibrinolytic Agents
Blood Coagulation Factors - metabolism
Child
Child, Preschool
Drug Administration Schedule
Drug Therapy, Combination
Female
Fibrinolysin - metabolism
Fibrinolysis
Heparin - administration & dosage
heparin-urokinase-pulse combined therapy, α2-plasmin inhibitor · plasmin complex (α2-PI · PmC), tissue-plasminogen activator (t-PA), coagulation factors, fibrinolytic factors
Humans
Male
Nephritis - blood
Nephritis - drug therapy
Tissue Plasminogen Activator - metabolism
Urokinase-Type Plasminogen Activator - administration & dosage
title Changes of coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T04%3A07%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20of%20coagulation%20and%20fibrinolytic%20factors%20observed%20during%20heparin-urokinase-pulse%20combined%20therapy%20for%20nephritis%20resistant%20to%20conventional%20treatment%20in%20children&rft.jtitle=Nihon%20Jinzo%20Gakkai%20shi&rft.au=KOITABASHI,%20YASUSHI&rft.date=1993-10&rft.volume=35&rft.issue=10&rft.spage=1155&rft.epage=1161&rft.pages=1155-1161&rft.issn=0385-2385&rft.eissn=1884-0728&rft_id=info:doi/10.14842/jpnjnephrol1959.35.1155&rft_dat=%3Cproquest_pubme%3E76146670%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76146670&rft_id=info:pmid/7505345&rfr_iscdi=true